Osivax has released phase 2a trial data confirming that its broad-spectrum flu vaccine candidate, OVX836, can be safely co-administered with the seasonal inactivated vaccine Fluarix Tetra.
The results, now published in Vaccines, show that the combination was well-tolerated with no serious adverse events, and generated strong immune responses.
The OVX836-004 study enrolled 180 healthy adults aged 18 to 55, each receiving intramuscular injections of either Fluarix Tetra with OVX836, Fluarix Tetra with placebo, or OVX836 with placebo.
Comparable local and systemic reactions were reported across all treatment groups, and HA-specific antibody responses remained consistent across all four influenza strains.
Robust NP-specific humoral and cell-mediated immune responses were observed in all participants given OVX836, whether alone or with Fluarix Tetra.
Dr Nicola Groth, CMO of Osivax, said: “The favorable safety profile and strong immune response observed in this study provide encouraging evidence that OVX836 can be co-administered with a standard seasonal influenza vaccine.”
Alexandre Le Vert, CEO and Co-Founder of Osivax, added: “By inducing strong and complementary immune responses, our approach positions us to meaningfully advance influenza prevention on a broader scale.”
The company is developing a single-injection formulation to simplify delivery and improve public health outcomes, especially in years when strain mismatches limit seasonal vaccine effectiveness.
